MacroGenics reports Thursday after the bell. Three separate signals are flashing at once — and they don't all agree.
SI hit 6% of free float on May 13. That's up 25% in a single day and 28% on the week. It's the biggest one-day jump in weeks.
The timing is deliberate. Earnings land May 15. Short sellers are positioning now.
Days to cover stands at 5.52 per the latest FINRA fortnightly data. That's meaningful for a small-cap biotech.
Cost to borrow spiked to 4.56% on May 5. That was nearly 8x the late-April rate of 0.29%. Then it collapsed — sitting at 1.11% as of May 13.
That round-trip matters. A CTB spike followed by a sharp retreat can signal short sellers locking in borrows early, then closing or covering ahead of the event. Availability has tightened sharply in tandem. The 52-week high on borrow pool usage was hit on May 13 — the tightest the lending market has been all year.
The put-call ratio sits at 0.24. That's roughly double the 20-day average of 0.15. The PCR z-score is 1.32 — elevated, not extreme.
Context matters here. The 52-week PCR high is 1.07. Current levels are far from panic. But the directional shift — from 0.07 in mid-April to 0.27 now — is consistent with protective positioning ahead of a binary event.
B. Riley upgraded MGNX to Buy on April 10, tripling their target to $9. Barclays raised its target to $6 from $4 on April 20, maintaining Overweight.
The mean analyst target is $6.75 — nearly double the current price of $3.45.
That gap matters. The stock has a recent history of violent earnings moves. The March 2026 print triggered a +54% single-day jump. The one before that moved +10% on day one and +40% over five days.
Bears are betting differently. MGNX reported a GAAP net loss of $41M last quarter. Revenue of $13M missed expectations. The pipeline is promising but pre-revenue.
What to watch: How the stock moves in the first 30 minutes post-earnings will determine whether the short build was prescient or becomes fuel for a squeeze.
See the live data behind this article on ORTEX.
Open MGNX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
